Pomerantz Law Firm Files Class Action Against Regencell Bioscience Holdings for Alleged Securities Violations

Class Action Lawsuit Filed by Pomerantz Against Regencell Bioscience Holdings

On June 11, 2026, the Pomerantz Law Firm announced a significant step in legal action against Regencell Bioscience Holdings Limited, commonly referred to as Regencell. The firm has filed a class action lawsuit in the United States District Court for the District of Maryland under case number 26-cv-01602. This lawsuit is particularly important for investors who acquired Regencell’s securities between October 28, 2024, and October 31, 2025—a period that the firm has defined as significant for claiming damages due to alleged violations of federal securities laws.

Details of the Class Action

All individuals or entities who purchased Regencell’s securities during the aforementioned class period are eligible to join the lawsuit, which aims to recover damages caused by the actions of the company's officers and executives. Investors interested in taking further steps are urged to contact Pomerantz Law Firm by June 23, 2026, to discuss the possibility of being appointed as Lead Plaintiff in this case. Relevant documents for the lawsuit can be accessed through Pomerantz's website.

What is Regencell?

Regencell positions itself as an early-stage bioscience company focused on the research and development of Traditional Chinese Medicine (TCM). Their purported goal is to address conditions such as Attention-Deficit/Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), which are generally deemed incurable by conventional medicine. Their strategy reportedly diverges from traditional treatments by aiming to tackle the fundamental causes of neurocognitive disorders rather than just alleviating symptoms.

As reported, Regencell is classified as a controlled company on the Nasdaq Capital Market, with a high degree of ownership concentrated among its executives—88.8% of shares being held by insiders as of June 30, 2025. Yat-Gai Au, Regencell’s founder and CEO, is noted to hold a substantial portion of the company's shares, potentially indicating conflicts of interest.

Stock Price Surge and Volatility

Investors have witnessed a dramatic episode with Regencell’s stock, which saw ordinary shares trading at under 30 cents before an extraordinary rise to $78.00 per share by June 17, 2025. This increase, astounding at 48,650% from the start of the class period, has drawn scrutiny given the absence of any solid business fundamentals to justify such a surge. By contrast, the significantly reduced stock price of around $27 to $29 at the time of this complaint filing raises further questions about possible market manipulation or misrepresentation by the company’s officers.

Despite claims of tackling major health disorders, Regencell has reported minimal research and development expenditure amounting to only $0.95 million and $1.07 million for the periods ended June 30, 2025, and 2024, respectively. This contrasts starkly with the industry’s typical new medicine costs estimated at approximately $4 billion, highlighting potential discrepancies in claims made by the company about their capabilities.

In January 2026, the Wall Street Journal pointed out that Regencell holds a market value around $14 billion—disturbingly high given its actual product and revenue status. Shortly after, significant stock price fluctuations were reported, linked to potential market manipulation and truths about the company's operational risks.

Allegations of Misleading Conduct

The class action complaint asserts that throughout the alleged misconduct period, Regencell and its higher-ups made numerous misleading statements regarding the company’s operational status, compliance policies, and exposure to market manipulation. Notably, they failed to adequately disclose the risks associated with the volatility surrounding their shares or the likelihood of regulatory scrutiny, thus putting investors at significant financial risk.

A pivotal moment surfaced on October 31, 2025, when Regencell informed investors of a federal investigation instigated by the U.S. Department of Justice (DOJ) into their stock trading practices. This disclosure correlated with an 18.56% drop in share value, illustrating the immediate impact of the information on market perception and investor confidence.

Conclusion

Pomerantz LLP, with a rich history of combating securities fraud and corporate misconduct, continues its commitment to protecting investors. The filing of this class action lawsuit against Regencell Bioscience Holdings raises pressing questions about corporate governance and market practices, calling for accountability from those at the helm of the company. Investors who suspect misleading conduct or potential financial loss are encouraged to assess their positions and consider joining the class action as it develops.

To learn more about participating in this class action, potential investors can reach out to Danielle Peyton at Pomerantz LLP or visit their official website for further instructions and needed documentation.